Managing Product Controversy: A Medical Liaison Point Of View

•

1 like•678 views

Scott Kraun

DIA 19th Annual Conference on Medical Communications, Medical Information, Medical Liaisons, And Contact Centers

Overview ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

An Opportunity In Disguise? ,[object Object],[object Object],[object Object],[object Object]

Importance Of The MLs ,[object Object],[object Object],[object Object]

MLs And HQ Strategy Development ,[object Object],[object Object],[object Object],[object Object],[object Object]

MLs And Controversy Control ,[object Object],[object Object],[object Object],[object Object],[object Object]

Communication Challenges ,[object Object],[object Object],[object Object],[object Object],[object Object]

ML Customer Communications ,[object Object],[object Object]

ML Customer Communications Cont’d. ,[object Object],[object Object],[object Object],[object Object]

ML Customer Communications Cont’d. ,[object Object],[object Object],[object Object]

Information Flow ,[object Object],[object Object]

Maximizing Relationship Marketing ML Medical Info Available Speakers Regional KOLs Speakers Global/US KOLs Managed Care INFLUENCE INFLUENCE High Volume Prescribers

Quote ,[object Object],[object Object],[object Object]

Summary ,[object Object],[object Object],[object Object],[object Object],[object Object]

Viewers also liked

SMA_Webinar_June10_2015_SFEImpact

Eric Scott

Development Msl

dlcram

Transitions of Care Medication Safety

hedavidson

Social Media In Pharma-Case Study Of Medical Science Liaison World

Medical Science Liaison Society

What is a Medical Science Liaison?

Medical Science Liaison Society

Medical Science Liaison (MSL) and KOL Regulatory Compliance

Medical Science Liaison Society

Scientific Advisors (SAs), Medical Advisors (MAs) and Medical Science Liaisons (MSLs) play a critical function within Medical Affairs departments of pharmaceutical, biotech and medical device companies. These typically highly educated and experienced professionals evaluate, critique and communicate comprehensive scientific information related to a company’s products. While differences in job titles, backgrounds and day-to-day activities can vary across companies and regions, MSLs and advisors are critical to improving understanding amongst internal departments and supporting product awareness across the broader medical community. They are credible peers on whom thought leaders can rely for current, objective and thorough information about disease states and treatments. They assist clinical teams, often support and help train the sales force, and develop relationships with key opinion leaders, among other activities. MSLs/Advisors are key players in the achievement of corporate business objectives in the fiercely competitive European marketplace. ExL Pharma’s MSL Best Practices conference has a long and established history in the United States, with seven highly successful and valuable MSL events taking place throughout America over a five year period. These conferences continue to attract more and more industry professionals, and have solidified ExL Pharma as a leader in the provision of relevant and practical information for Medical Affairs professionals. From the US-based events, a need was assessed for a similar conference to take place in Europe. Thus, the European MSL & Medical/Scientific Advisor Best Practices conference was born. We are excited to offer this unique opportunity in Europe for MSLs and Advisors throughout the industry to gather to share successful strategies for both field-based and office-based activities. Through the provision of case studies and educational presentations led by experienced industry professionals, ample networking time and interactive sessions, MSLs and Advisors are sure to gain take-home approaches for providing maximum value to key opinion leaders, the company and the industry as a whole. We look forward to greeting you in London!

ExL Pharma's European Medical Science Liaison Conference Brochure, October, L...

ExL Pharma

Viewers also liked (7)

SMA_Webinar_June10_2015_SFEImpact

Development Msl

Transitions of Care Medication Safety

Social Media In Pharma-Case Study Of Medical Science Liaison World

What is a Medical Science Liaison?

Medical Science Liaison (MSL) and KOL Regulatory Compliance

ExL Pharma's European Medical Science Liaison Conference Brochure, October, L...

Similar to Managing Product Controversy: A Medical Liaison Point Of View

Best in-class Medical Science Liasons

Jean-Michel Peny

Scott Kraun's presentation on the added value Medical Liaisons (MLs) offer their organizations during times of controversy (product, legal/regulatory, corporate, etc.). As the primary initiators of relationships with clinical investigators, Key Opinion Leaders (KOLs), and other medical authorities, these teams warrant inclusion as “front-line” messengers in standing crisis communication plans.

Managing Controversy - A Medical Liaison Point Of View - Scott Kraun.pdf

Scott Kraun

Highlights From 7th Medical Science Liaison/MSL Conference

ExL Pharma

Medical Science Liaison Webinarv 2009

Cameron Tew

Agenda- 2nd Annual Customer Centric Medical Information

Rachel Starnes

The 7 Essentials of Successful Health Economic Communication

Covance

Towards Value Innovation In Pharma SFE Conference London 062007

A.R.J. (Rob) Halkes

Unlocking Hidden Insights for Pharma with Social Media Listening

RNayak3

7 Essentials of Health Economic Communication | Market Access Services

Covance

Customer Experience Management: What are the essential ingredients for delivering a successful CX programme? All in it together? There is a tendency for pharma to think in silos - how can this be challenged to deliver coherent company-wide customer communications? Same goal, different needs: How can pharma meet the differing content and communication preferences of physicians and other healthcare professionals? Something different: How will high levels of customer satisfaction differentiate your product in a crowded market place and encourage wider use? Getting it wrong: Why do so many digital initiatives fail to engage physicians and HCPs? Wider support: How can stakeholders work with pharma to create a mutually beneficial customer experience?

Customer Experience (CX) in Physician and HCP Engagement

MarketResearch.com

Cerner corporation presentation

lmthoman

Patient Advocacy Groups Benefits To Oncology Commercialization [www.BiomedwoR...

Michael W. Young

Future Solutions from Qualitative Big Data

Dr Avnesh Ratnanesan (Avi)

什么是公共关系？

LONGAID

PR for Healthcare Providers, Biotech & Medical Device Companies

G2 Communications, Inc.

How to Turn Medical Science into Great PR!

G2 Communications, Inc.

Chapter 7 Preview Review IDIC Framework: Interact Communication Becomes Interaction Dialogue Requirements Implicit and Explicit Bargains Two-Way, Addressable Media Integrating Interaction across the Enterprise Touchpoint Mapping Customer Dialogue Complaining Customers, Hidden Assets Managing Customer Relationships: A Strategic Framework, Third Edition, Don Peppers and Martha Rogers 1 1 Action Analysis …customers as unique addressable individuals …by value, behavior and needs …more cost -efficiently and effectively …some aspect of the company’s behavior, offerings, or communications Identify Differentiate Interact Customize Review: IDIC Framework COPYRIGHT © 2009. ALL RIGHTS PROTECTED AND RESERVED. ‹#› 2 Communication becomes Interaction Traditional marketing communication: generate messages about your organization Customer-strategy communication: interaction, or generating feedback from customers to create a collaborative feedback loop Managing Customer Relationships: A Strategic Framework, Third Edition, Don Peppers and Martha Rogers 3 3 Dialogue Requirements Parties at both ends have been clearly identified All parties in the dialogue must be able to participate in it All parties to a dialogue must want to participate in it Dialogues can be controlled by anyone in the exchange A dialogue with an individual customer will change an enterprise’s behavior toward that individual (and vice versa) A dialogue should pick up where it last left off Managing Customer Relationships: A Strategic Framework, Third Edition, Don Peppers and Martha Rogers 4 4 Implicit and Explicit Bargains Implicit bargains Expressed through nonaddressable (one-way) media Example: early television commercials - “Watch our ad and see the show for free.” Explicit bargains Made possible through addressable (two-way) media Example: website operators that offer free e-mail to individuals willing to view targeted advertisements Dialogue and interaction are so valuable that enterprises offer free services or discounts to customers willing to participate Managing Customer Relationships: A Strategic Framework, Third Edition, Don Peppers and Martha Rogers 5 5 Two-Way, Addressable Media World Wide Web Social media Wireless technology Voicemail E-mail Texting Fax Digital video recorders Interactive voice response Managing Customer Relationships: A Strategic Framework, Third Edition, Don Peppers and Martha Rogers 6 6 Integration of Interaction across the Enterprise Laterally coordinated across media types Longitudinally coordinated over the individual customer’s relationship with the firm Results in customer’s conversation with firm picking up exactly where it left off – no matter what channel was used last time Managing Customer Relationships: A Strategic Framework, Third Edition, Don Peppers and Martha Rogers 7 7 Touchpoint Mapping Dimensions of customer experience: Physical – location based Emotional – related to culture o ...

Chapter 7 PreviewReview IDIC Framework InteractCommunicat

simisterchristen

We are entering a new era of the ARO, one that challenges the current paradigm of clinical development and the numerous offerings of CROs. It will not be long before AROs play a more central role in pharmaceutical clinical development plans. AROs, like Julius Clinical, have evolved over the years, giving rise to various definitions of what an ARO is and what it isn’t. In this opinion piece, published in the European Pharmaceutical Contractor (EPC) magazine, Cyrus Park highlights four common misperceptions about academic research organizations (AROs) and attempts to dispel some of the misconceptions from his own observations. The full article can be read here.

Lighting the Way - The Era of the ARO (European Pharmaceutical Contractor, Au...

Cyrus Park

PBH.815 Week 2 Lecture

Gina Crosley-Corcoran

LS e-book

Christopher Cestaro

Similar to Managing Product Controversy: A Medical Liaison Point Of View (20)

Best in-class Medical Science Liasons

Managing Controversy - A Medical Liaison Point Of View - Scott Kraun.pdf

Highlights From 7th Medical Science Liaison/MSL Conference

Medical Science Liaison Webinarv 2009

Agenda- 2nd Annual Customer Centric Medical Information

The 7 Essentials of Successful Health Economic Communication

Towards Value Innovation In Pharma SFE Conference London 062007

Unlocking Hidden Insights for Pharma with Social Media Listening

7 Essentials of Health Economic Communication | Market Access Services

Customer Experience (CX) in Physician and HCP Engagement

Cerner corporation presentation

Patient Advocacy Groups Benefits To Oncology Commercialization [www.BiomedwoR...

Future Solutions from Qualitative Big Data

什么是公共关系？

PR for Healthcare Providers, Biotech & Medical Device Companies

How to Turn Medical Science into Great PR!

Chapter 7 PreviewReview IDIC Framework InteractCommunicat

Lighting the Way - The Era of the ARO (European Pharmaceutical Contractor, Au...

PBH.815 Week 2 Lecture

LS e-book